Pay in 4 interest-free payments of $6.86 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
After a five-day gap, your next seven-day gap feels longer by comparison
Call if youre looking to find a provider to assist you with your health and wellness
The FDA initially approved subcutaneous (SC) use Exenatide in 2005 and an oral version of semaglutide in 2019.2,3 Initially, GLP-1s were used exclusively for individuals with type 2 diabetes (T2DM) as a means to better control their blood sugar when paired with diet and exercise.2 Now their use is growing exponentially due to their success in helping patients achieve significant weight loss
While patients are showing some willingness to absorb cost hikes associated with reduced payer coverage for GLP-1 drugs, theyre far from the only stakeholders to be impacted by shifting policies: Biopharma Pharmaceutical developers could face slower market growth, particularly for newer indications like cardiovascular risk reduction and addiction treatment
US$ 26.18
US$ 21.60
US$ 21.02
